Literature DB >> 24696731

Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.

Jun Li1, Chang Sheng2, Wei Li3, Jun-Hua Zheng3.   

Abstract

BACKGROUND: Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases. It positively regulates apoptosis and negatively regulates the mitogenic pathway, suggesting that loss of it might be involved in cancer development. Recent studies found its association with breast, lung and colorectal cancer; however, its expression profile and its prognostic value in clear cell renal cell carcinoma (ccRCC) have not been investigated.
METHODS: Real-time quantitative PCR (qRT-PCR) and Western blot were used to explore PP2A expression in ccRCC and normal renal tissues. Moreover immunohistochemistry (ICH) was used to detect the expression of PP2A in ccRCC. Spearman's rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the data.
RESULTS: Down-regulated expression of PP2A mRNA and protein was observed in the majority of ccRCC by qRT-PCR and Western blot when compared with their paired normal renal tissues. Clinic pathological analysis was showed a significant correlation existed between the lower expression of PP2A protein with the histological grade, lymph node metastasis and tumor distant metastasis (P<0.05); Survival analysis by Kaplan-Meier survival curve and log-rank test demonstrated that reduced PP2A expression in cancer tissue predicted poorer overall survival (OS) compared with group in higher expression. Notably, multivariate analyses by Cox's proportional hazard model revealed that expression of PP2A was an independent prognostic factor in ccRCC.
CONCLUSIONS: These results suggest that the aberrant expression of PP2A in human ccRCC is possibly involved with tumorigenesis and development, and the PP2A protein could act as a potential biomarker for prognosis assessment of renal cancer. Further studies on the cellular functions of PP2A need to address these issues.

Entities:  

Keywords:  PP2A; Phosphatase-2A; biomarker; clear cell renal cell carcinoma; prognosis; serine-threonine phosphatases

Mesh:

Substances:

Year:  2014        PMID: 24696731      PMCID: PMC3971320     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  22 in total

Review 1.  PP2A: unveiling a reluctant tumor suppressor.

Authors:  Marc Mumby
Journal:  Cell       Date:  2007-07-13       Impact factor: 41.582

Review 2.  Serine/threonine protein phosphatases.

Authors:  S Wera; B A Hemmings
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

Review 3.  Regulation of protein kinase cascades by protein phosphatase 2A.

Authors:  T A Millward; S Zolnierowicz; B A Hemmings
Journal:  Trends Biochem Sci       Date:  1999-05       Impact factor: 13.807

Review 4.  Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

Authors:  V Janssens; J Goris
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

5.  Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.

Authors:  Sujata Patil; Nicole Ishill; John Deluca; Robert J Motzer
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

6.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

Review 7.  Multiple pathways regulated by the tumor suppressor PP2A in transformation.

Authors:  Jukka Westermarck; William C Hahn
Journal:  Trends Mol Med       Date:  2008-03-10       Impact factor: 11.951

8.  The tumor suppressor PP2A Abeta regulates the RalA GTPase.

Authors:  Anna A Sablina; Wen Chen; Jason D Arroyo; Laura Corral; Melissa Hector; Sara E Bulmer; James A DeCaprio; William C Hahn
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

9.  Protein kinases and phosphatases in the control of cell fate.

Authors:  Angela Bononi; Chiara Agnoletto; Elena De Marchi; Saverio Marchi; Simone Patergnani; Massimo Bonora; Carlotta Giorgi; Sonia Missiroli; Federica Poletti; Alessandro Rimessi; Paolo Pinton
Journal:  Enzyme Res       Date:  2011-09-04

Review 10.  PP2A-Mediated Anticancer Therapy.

Authors:  Weibo Chen; Zhongxia Wang; Chunping Jiang; Yitao Ding
Journal:  Gastroenterol Res Pract       Date:  2013-11-07       Impact factor: 2.260

View more
  3 in total

1.  miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA.

Authors:  Francesca Maria Orlandella; Raffaela Mariarosaria Mariniello; Paola Lucia Chiara Iervolino; Esther Imperlini; Annalisa Mandola; Anna Verde; Anna Elisa De Stefano; Katia Pane; Monica Franzese; Silvia Esposito; Fulvio Basolo; Stefania Orrù; Giuliana Salvatore
Journal:  Endocrine       Date:  2019-03-29       Impact factor: 3.633

2.  Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac.

Authors:  Min Tao; Lu Liu; Meng Shen; Qiaoming Zhi; Fei-Ran Gong; Binhua P Zhou; Yadi Wu; Haiyan Liu; Kai Chen; Bairong Shen; Meng-Yao Wu; Liu-Mei Shou; Wei Li
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer.

Authors:  Shinsuke Hanawa; Akira Mitsuhashi; Makio Shozu
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.